Company / EPS (Basic)
Cardiff Oncology, Inc. EPS (Basic) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$0.95
FY2025
5-year range
-$1.08 / -$0.73
FY2021-FY2025
Trend
-2.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
EPS (Basic) has declined for 3 consecutive years, from $-0.73 in FY2022 to $-0.95 in FY2025.
Based on SEC 10-K filings.
-0.95 in FY2025.
Declined from $-0.89 to $-0.95 over the past 2 years.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- Cardiff Oncology, Inc.'s eps (basic) has declined for 3 consecutive years.
- In FY2025, eps (basic) decreased 2.2% year-over-year.
- Peak eps (basic) was recorded in FY2022.
- Lowest eps (basic) in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.67 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.95 | -2.2% |
| FY2024 | -$0.93 | -4.5% |
| FY2023 | -$0.89 | -21.9% |
| FY2022 | -$0.73 | +32.4% |
| FY2021 | -$1.08 | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | -$51.76 | -3881.5% |
| FY2017 | -$1.30 | -71.1% |
| FY2016 | -$0.76 | -8.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026